Background {#Sec1}
==========

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related death worldwide \[[@CR1]\]. Gastrectomy with prophylactic lymphadenectomy is the basic surgical concept for GC, and treatment outcomes have been improving with advances in surgical techniques \[[@CR2], [@CR3]\]. In patients with early GC (EGC), D1/D1+ or D2 is adopted for those with cN0 or cN+, respectively \[[@CR4]\]. On the other hand, in patients with advanced GC (AGC), D2 has been uniformly performed regardless of cN because the incidence of pN+ is high but difficult to precisely predict \[[@CR4]\]. Preoperative assessment of lymph node metastasis is generally performed by computed tomography (CT) \[[@CR5]\]; however, the diagnostic accuracy for pN+ is not sufficient and should be improved using another diagnostic tool.

Cancer-related inflammation was previously confirmed as a key determinant of cancer progression, and systemic inflammation is associated with alterations in peripheral blood leukocytes that are reflected in the neutrophil-to-lymphocyte ratio (NLR) \[[@CR6]--[@CR8]\]. Therefore, NLR may be a complementary diagnostic tool for pN+. There are many reports demonstrating the prognostic impact of NLR in different cancers \[[@CR9]--[@CR11]\]; however, few studies have examined whether NLR is useful for predicting pN+ in comparison with conventional diagnostic modalities.

In the present study, the diagnostic accuracy of NLR for pN+ was compared with that of conventional modalities such as CT. The aim of this study was to explore the clinical significance of NLR as a predictor of pN+ in GC, and to examine whether NLR can improve the diagnostic accuracy for pN+ in combination with conventional modalities.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between January 2008 and May 2013, 578 patients underwent surgical treatment for GC at the Division of Digestive Surgery of Kyoto Prefectural University of Medicine (KPUM). Among these patients, this study examined only those who underwent CT followed by curative gastrectomy (R0). The following exclusion criteria were applied to potential subjects of this study: active infection, chronic inflammatory or autoimmune diseases, chronic use of steroid and/or immunosuppressive agents, hematological disorders, lack of information on preoperative complete blood counts, distant metastasis of GC, and simultaneous malignancies other than GC. In addition, to exclude the potential effects of treatment factors on the diagnostic accuracy for pN+, patients who underwent non-curative surgery (R1/R2) and those undergoing neoadjuvant chemotherapy (NAC) were also excluded. In contrast to Western countries, NAC has not been the standard treatment for GC even with advanced stage in Japan \[[@CR4]\]. In total, 429 patients were included in this retrospective study.

Assessment of NLR {#Sec4}
-----------------

The preoperative cell blood count (CBC) and differential white blood cell count (WBC), including neutrophils and lymphocytes, were measured within one week before surgery. NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count.

Assessment of cT and cN {#Sec5}
-----------------------

All patients received upper endoscopy, barium meal examination, and chest and abdominal CT prior to surgery. The clinical T stage (cT) was assessed using upper endoscopy, barium meal examination, and abdominal CT findings by gastroenterologists and radiologists. The clinical N stage (cN) was diagnosed using the chest and abdominal CT findings by at least two radiologists. CT was performed at KPUM or Oike Clinic (Kyoto, Japan), a consociated medical center, employing a multidetector CT with 64 or 320 layers. Contrast-enhanced CT (CECT) with iopamidol or iohexol was the recommended standard, but patients who had iodine allergy, active asthma, or poor thyroid, heart, liver or renal function underwent plain CT without the contrast agents. Lymph nodes exhibiting a minor axis of 8 mm or greater or a major axis of 10 mm or greater on CT were regarded as "cN+" according to previous studies \[[@CR5], [@CR12], [@CR13]\]. Endoscopic ultrasound (EUS) was not used for the evaluation of cN.

Assessment of pT and pN {#Sec6}
-----------------------

All patients underwent R0 surgery consisting of gastrectomy and lymphadenectomy based on the Japanese GC treatment guidelines (JGCTG) \[[@CR4]\]. All resected specimens were microscopically examined by at least two pathologists, and the pathological T and N stages (pT and pN) were evaluated based on the current Japanese classification of GC (JCGC) \[[@CR14]\].

Statistical analysis {#Sec7}
--------------------

To evaluate the discriminatory ability of the NLR for pN+, receiver operating characteristic (ROC) curves were generated and the area under the ROC curve (AUROC) was measured. The optimal cut-off value of NLR was determined by the Youden index (*J*) \[[@CR15], [@CR16]\]. *J* is defined as the maximum vertical distance between the ROC curve and the diagonal or chance line and is calculated as *J* = maximum {sensitivity + specificity − 1} \[[@CR15], [@CR16]\]. Chi-square tests and Wilcoxon rank sum tests were used to compare categorical and continuous variables, respectively, between the two groups. In analyses of related factors for pN+, the clinical variables with *p* \< 0.05 in the univariate analysis were incorporated into the multivariate analysis to identify independent factors. All statistical analyses were performed using JMP 13 (SAS Institute, Cary, NC, USA), and *p* \< 0.05 was set as the level of significance.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

The clinical and pathological characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. Patients were diagnosed with cT1 (*n* = 277) or cT2-T4 (*n* = 152), and pathologically diagnosed with pT1 (n = 277) or pT2-T4 (n = 152). Seventy-three patients (17.0%) were diagnosed with cN+ by conventional diagnostic modalities, and 116 patients (27.0%) were pathologically diagnosed with pN+. The incidence of pN+ in cT2-T4 was 56.6%, which was higher than that (10.8%) in cT1 (*p* \< 0.001). The preoperative NLR ranged from 0.6 to 10.8 (median, 2.0). The NLR value for patients with cT2-T4 was 2.6 ± 1.5 (mean ± standard deviation (SD)), which was higher than that (2.2 ± 1.2) for those with cT1 (*p* = 0.037). Table 1Clinicopathological characteristics of the patientscT1-T4 (*n* = 429)cT1 (*n* = 277)cT2-T4 (*n* = 152)*P* valueClinical characteristics Sex, n (%)0.341  Male278 (64.8)175 (63.2)103 (67.8)  Female151 (35.2)102 (36.8)49 (32.2) Age (years)0.016  Median (range)67 (29--89)66 (35--89)69 (29--89)  Mean ± SD65.6 ± 11.464.7 ± 11.267.1 ± 11.7 Tumor location, n (%)\< 0.001  Upper108 (25.2)67 (24.2)41 (27.0)  Middle204 (47.6)154 (55.6)50 (32.9)  Lower117 (27.3)56 (20.2)61 (40.1) cT, n (%)--  T1277 (64.6)277 (100)--  T2116 (27.0)--116 (76.3)  T334 (7.9)--34 (22.4)  T42 (0.5)--2 (1.3) cN, n (%)\< 0.001  N0 (negative)356 (83.0)267 (96.4)89 (58.6)  N+ (positive)73 (17.0)10 (3.6)63 (41.4) NLR0.037  Median (range)2.0 (0.6--10.8)2.0 (0.6--10.8)2.1 (0.6--10.5)  Mean ± SD2.3 ± 1.32.2 ± 1.22.6 ± 1.5Pathological characteristics pT, n (%)\< 0.001  T1277 (64.6)245 (88.4)32 (21.1)  T249 (11.4)16 (5.8)33 (21.7)  T362 (14.5)14 (5.1)48 (31.6)  T441 (9.6)2 (0.7)39 (25.6) pN, n (%)\< 0.001  N0 (negative)313 (73.0)247 (89.2)66 (43.4)  N+ (positive)116 (27.0)30 (10.8)86 (56.6)*SD* standard deviation, *NLR* neutrophil-to-lymphocyte ratio

NLR according to cN and pN {#Sec10}
--------------------------

The NLR value for patients with cN+ or cN0 was 2.4 ± 1.3 or 2.3 ± 1.3 (mean ± SD), respectively (*p* = 0.921). The NLR value for patients with pN+ was 2.6 ± 1.5 (mean ± SD), which was higher than that (2.2 ± 1.2) for those with pN0 (*p* = 0.003).

ROC curve analysis {#Sec11}
------------------

The optimal cut-off value of NLR for predicting pN+ was 1.6 according to the ROC curve using the maximal Youden index (AUROC, 0.595; sensitivity, 83.6%; specificity, 36.4%) (Fig. [1](#Fig1){ref-type="fig"}). Thereafter, all subjects were divided into two groups as follows: the low NLR (NLR \< 1.6) and high NLR (NLR ≥ 1.6) groups. Fig. 1ROC curve for NLR for predicting pN+ in patients with gastric cancer. ROC: receiver operating characteristic, NLR: neutrophil-to-lymphocyte ratio, AUC: area under the curve

Clinical factors associated with pN+ in GC {#Sec12}
------------------------------------------

The univariate and multivariate analyses of clinical factors associated with pN+ in patients with EGC (cT1) or AGC (cT2-T4) are shown in Table [2](#Tab2){ref-type="table"}. In patients with cT1, the univariate logistic analysis showed that a NLR ≥ 1.6 was not significantly associated with pN+ (odds ratio (OR) 2.253; 95% confidence interval (CI) 0.942--6.266, *p* = 0.069), and cN+ was significantly correlated with pN+ (OR 9.680; 95% CI 2.537--37.07, *p* = 0.002). However, in patients with cT2-T4, the univariate and multivariate logistic regression analysis identified NLR (OR 3.171; 95% CI 1.448--7.235, *p* = 0.004) and cN (OR 2.426; 95% CI 1.221--4.958, *p* = 0.011) to be independently associated factors with pN+. Table 2Clinical factors associated with pN+ in patients with early or advanced gastric cancerA: Early gastric cancer (cT1) (*n* = 277)VariablesPathological lymph node metastasis (pN+) (*n* = 30)UnivariateMultivariateOR95% CI*p* valueOR95% CI*p* valueSex0.704 Male1 Female1.1630.524--2.503Age0.629  \< 651.2050.561--2.590  ≥ 651Tumor location0.353 Upper1.4640.644--3.189 Middle/Lower1cN0.002 N01 N+9.6802.537--37.07NLR0.069 Low (\< 1.6)1 High (≥1.6)2.2530.942--6.266B: Advanced gastric cancer (cT2-T4) (*n* = 152)VariablesPathological lymph node metastasis (pN+) (*n* = 86)UnivariateMultivariateOR95% CI*p* valueOR95% CI*p* valueSex0.424 Male1 Female1.3250.666--2.679Age0.496  \< 651  ≥ 651.2630.644--2.476Tumor location0.968 Upper1 Middle/Lower1.0140.518--1.975cN0.0140.011 N011 N+2.3001.183--4.5732.4261.221--4.958NLR0.0050.004 Low (\< 1.6)11 High (≥1.6)3.0041.399--6.6873.1711.448--7.235*NLR* neutrophil-to-lymphocyte ratio

Clinical value of NLR as a predictor of pN+ in advanced GC {#Sec13}
----------------------------------------------------------

The diagnostic accuracy of NLR or conventional modalities for pN+ in patients with AGC (cT2-T4) is shown in Table [3](#Tab3){ref-type="table"}. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of a NLR ≥ 1.6 for pN+ were 84.9, 34.8, 62.9, 63.9, and 63.2%, respectively. Thus, the sensitivity was higher, specificity was lower, and diagnostic accuracy was slightly higher than those (50.0, 69.7, and 58.6%, respectively) of conventional modalities. Next, the predictive ability of NLR for pN+ was separately examined according to cN (N0 or N+) (Table [4](#Tab4){ref-type="table"}). When the subjects were limited to AGC patients with cN0, the sensitivity and NPV of a NLR ≥ 1.6 for pN+ increased further (90.7 and 81.0%, respectively). Table 3Diagnostic accuracy for pN+ in patients with advanced gastric cancerA: Conventional modalities (CT)pN+pN0ncN+432063cN0434689n8666152B: NLRpN+pN0nHigh NLR (≥1.6)7343116Low NLR (\<1.6)132336n8666152C: Diagnostic accuracy for pN+cN+High NLR (≥1.6)Sensitivity50.0 % (95% CI: 43.2-56.2)84.9 % (95% CI: 78.9-90.1)Specificity69.7 % (95% CI: 60.8-77.8)34.8 % (95% CI: 27.1-41.6)Positive predictive value68.3 % (95% CI: 58.9-76.7)62.9 % (95% CI: 58.5-66.8)Negative predictive value51.7 % (95% CI: 45.1-57.7)63.9 % (95% CI: 49.7-76.3)Diagnostic accuracy58.6 % (95% CI: 50.8-65.6)63.2 % (95% CI: 56.4-69.0)*NLR* neutrophil-to-lymphocyte ratio Table 4Predictive ability of NLR for pN+ separately examined according to cN in patients with advanced gastric cancerA: cN0pN+pN0nHigh NLR (≥1.6)392968Low NLR (\<1.6)41721n434689Diagnostic accuracy for pN+High NLR (≥1.6)Sensitivity90.7 % (95% CI: 81.8-96.1)Specificity37.0 % (95% CI: 28.6-42.0)Positive predictive value57.4 % (95% CI: 51.7-60.8)Negative predictive value81.0 % (95% CI: 62.7-92.0)B: cN+pN+pN0nHigh NLR (≥1.6)341448Low NLR (\<1.6)9615n432063Diagnostic accuracy for pN+High NLR (≥1.6)Sensitivity79.1 % (95% CI: 72.6-86.3)Specificity30.0 % (95% CI: 16.0-45.5)Positive predictive value70.8 % (95% CI: 65.0-77.3)Negative predictive value40.0 % (95% CI: 21.3-60.7)*NLR* neutrophil-to-lymphocyte ratio

Discussion {#Sec14}
==========

Systemic inflammatory response plays an important role in cancer development and progression \[[@CR6]--[@CR8]\]. Therefore, the increase in NLR, due to the systemic inflammatory response induced by cancer, may be a novel diagnostic modality for pN+ in GC. In the present study, the preoperative NLR was demonstrated to be independently associated with pN+ in patients with AGC (cT2-T4), but not in those with EGC (cT1). In AGC, a NLR ≥ 1.6 detected pN+ with a higher sensitivity (84.9%) than that (50.0%) of the CT. The high sensitivity of the preoperative NLR suggests it to be a useful complementary modality in the assessment of pN+ in AGC.

The therapeutic strategy for GC, including the extent of gastric resection and lymphadenectomy, is determined based on cT (T1 or T2-T4) and cN (N0 or N+) \[[@CR4]\]. However, it is challenging to accurately predict the pathological tumor stage, particularly pN, because of the low diagnostic accuracy of conventional modalities \[[@CR5], [@CR12]\]. In the present study, the sensitivity, specificity, and diagnostic accuracy of CT for detecting pN+ (or pN0) in patients with AGC were as low as 50.0, 69.7, and 58.6%, respectively. On the other hand, the diagnostic accuracy for detecting pT2-T4 (or pT1) was 85.1% (Additional file [1](#MOESM1){ref-type="media"}: Table S1), which was easier to diagnose than pN. Positron emission tomography (PET) integrated with CT (PET-CT) may have played a role in the improved diagnostic accuracy for pN+ by increasing the specificity \[[@CR5]\]; however, the low sensitivity is one of the weak points of this modality. Therefore, the development of novel diagnostic tools is essential to increase the specificity and sensitivity for predicting pN+.

Most previous studies focused on a high NLR as a useful predictor of long-term outcomes in patients with GC \[[@CR10], [@CR17], [@CR18]\]. Indeed, in the targeted cohorts of the present study, the postoperative 5-year overall and cancer-specific survival rates of patients with a NLR ≥ 1.6 were significantly poorer than those with a NLR \< 1.6 (data not shown). However, few studies have assessed the clinical significance of NLR as a diagnostic tool for pN+ in GC. Shimada et al. reported that the mean preoperative NLR in GC patients with pN+ was 2.91, which was significantly higher than that (2.40) in patients with pN0 \[[@CR10]\], but the predictive ability of NLR for pN+ was not examined in detail. Zhang et al. estimated an optimal cutoff value of NLR of 2.0 (sensitivity, 52.6; specificity, 54.4; AUROC, 0.594), and a NLR ≥ 2.0 was significantly associated with pN+ by univariate analysis \[[@CR18]\]; however, they neither assessed the influence of potential confounding factors, such as cT and cN, nor compared the diagnostic ability with conventional diagnostic modalities.

The present study was the first to explore whether the preoperative NLR is a predictor for pN+ independent of cN+, and to examine the diagnostic accuracy of NLR for pN+ in comparison with conventional modalities. As a result, a NLR ≥ 1.6 was found to be an independent predictor for pN+ in AGC (cT2-T4) with a slightly higher OR than conventional diagnostic modalities. In EGC (cT1), however, cN+ was not significantly correlated with pN+. Although the small sample size may be one of the responsible factors for the negative result in cT1, our study suggested that NLR was not superior to conventional modalities for predicting pN+ among patients with cT1. The correlation between the NLR value and cT may also have affected the results; however, the cut-off values of NLR for predicting pN+ determined by the ROC curve were 1.7 for cT1 and 1.6 for cT2-T4 (data not shown), which were both similar to the value for cT1-T4. Meanwhile, a NLR ≥ 1.6 may also be a good predictor of pT2/T3/T4 (vs pT1); however, the diagnostic accuracy (48.3%) was lower than that (85.1%) of conventional modalities such as upper endoscopy, barium meal examination and abdominal CT (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Although it has the potential to predict pN+ independent of cN+, the diagnostic accuracy of a NLR ≥ 1.6 for pN+ in AGC was only 63.2%, which was comparable to that of cN+. Actually, in the McNemar test, there was not a significant difference in the diagnostic accuracy for pN+ between a NLR ≥ 1.6 and cN+ (*p* = 0.175) (data not shown). As the low specificity was the major reason for the poor diagnostic accuracy, attention should be paid to the high incidence of false-positive cases when using NLR to predict pN+. On the other hand, the high sensitivity of NLR for pN+ was of note, i.e., a NLR \< 1.6 may aid in the specific diagnosis of pN+. To clarify the most effective clinical use of NLR in combination with conventional diagnostic modalities, the predictive ability of NLR for pN+ was separately examined according to cN. When the subjects were limited to AGC patients with cN0, the sensitivity and NPV of a NLR ≥ 1.6 for pN+ increased further (90.7 and 81.0%, respectively). Therefore, a NLR \< 1.6 may aid in the prediction of pN0, especially in combination with conventional diagnostic modalities.

The present study had several limitations that should be considered. First, the retrospective and single-center nature of the study may have generated selection bias in the cohort, and the number of study patients was relatively small, which may have limited the statistical power. Second, as the cut-off value of NLR was calculated only by a mathematical method, the low specificity of a NLR ≥ 1.6 for pN+ is a problem to be solved. Third, unfortunately, we could not find a correlation between preoperative NLR value and the number of pathological positive lymph nodes (Spearman's rank correlation coefficient (ρ): 0.1224, *p* = 0.011) (data not shown); thus, it remains unclear whether biologically NLR is driving lymph node metastasis. Fourth, this study examined only NLR, but other immune-nutritional markers such as prognostic nutritional index (PNI) may also be useful predictors of pN+. However, to the best of our knowledge, this is the first report to present the novel potential of preoperative NLR for predicting pN in patients with AGC in comparison with conventional modalities. As the number of elderly patients with GC who have many comorbid diseases and poor organ function is increasing \[[@CR19]--[@CR22]\], limited lymph node dissection may be reasonable for such patients when pN0 is highly suspected based on the combined use of conventional modalities and NLR. The results of the present study and the optimal cut-off value of NLR need to be validated in further studies with large sample sizes to develop the sophisticated treatment strategies based on the reliable cN.

Conclusion {#Sec15}
==========

The preoperative NLR may be a useful complementary diagnostic tool in the assessment of pN+ in AGC because of its higher sensitivity and NPV than conventional diagnostic modalities.
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**Additional file 1: Table S1.** Diagnostic accuracy for pT2/T3/T4 in patients with gastric cancer.
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